Dicerna Pharmaceuticals, Inc. announced the appointment of Pankaj Bhargava, M.D., as Chief Medical Officer. Dr. Bhargava brings to Dicerna more than 15 years of experience in oncology drug development and translational research gained in leading industry and academic institutions. In his role as Chief Medical Officer, he will be responsible for clinical development activities as well as regulatory affairs.

Prior to joining Dicerna, Dr. Bhargava was Associate Vice President at Sanofi Oncology, where he led the global development of aflibercept (ZALTRAP(TM)) culminating in successful approvals by U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and several regulatory authorities worldwide. Prior to Sanofi, Dr. Bhargava was Vice President Clinical Research and Interim Chief Medical Officer at AVEO Pharmaceuticals where he oversaw the development of all of the company's clinical programs. Since October 2004, Dr. Bhargava has served as an attending physician at the Dana-Farber Cancer Institute and a faculty member at Harvard Medical School.